Common side effects of semaglutide include: Nausea Vomiting Diarrhea Stomach pain Decreased appetite Indigestion Belching Constipation Other side effects that are reported less commonly include: Headache Dizziness Fatigue Hair loss Muscle pain Injection site reactions (redness or irritation) Serious (and rare) side effects of semaglutide include: Low blood sugar (hypoglycemia) Pancreatitis (inflammation of the pancreas) Gallbladder disease Changes in vision (diabetic retinopathy) Allergic reactions Kidney problems Semaglutide may increase the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)
This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug available in pill form, after Wegovy, which gained approval in December 2025
It contains a preservative that prevents bacterial growth, allowing multi-use from a single vial
It is not a free pass continuous, non-pulsatile overstimulation is the theoretical concern behind why the short-acting, pulse-mimicking forms are generally preferred but the it will shut me down like a steroid worry is not how this class of compound works
Denial of branded coverage doesn't prevent access to the same molecule through 503B compounding
2022, NEJM) for Zepbound